Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive efficacy and safety data from the first cohort of its ongoing Phase 2a study of AZP–3601 in patients with hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR), which is being held September 9–12 in Austin, TX.
